Concept of hypercoagulability: a review of its development, clinical application, and recent progress.

abstract：:Non-Shiga toxin-associated hemolytic uremic syndrome (atypical HUS) is a rare form of thrombotic microangiopathy that associates hemolytic anemia, thrombocytopenia, and acute renal failure. The disease has been demonstrated to be linked with a complement alternative pathway dysregulation due to genetic defects but als...

journal_title：Seminars in thrombosis and hemostasis

authors： Dragon-Durey MA,Blanc C,Garnier A,Hofer J,Sethi SK,Zimmerhackl LB

更新日期：2010-09-01 00:00:00

abstract：:Molecular linkages between von Willebrand factor (VWF) and the alternative complement pathway (AP) have recently been discovered. Endothelial cell (EC)-anchored ultra-large (UL) VWF multimeric strings function as an activating surface for the AP. C3 (in active C3b form) binds to the EC-anchored ULVWF strings, and prom...

journal_title：Seminars in thrombosis and hemostasis

authors： Turner N,Nolasco L,Nolasco J,Sartain S,Moake J

更新日期：2014-07-01 00:00:00

abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

journal_title：Seminars in thrombosis and hemostasis

authors： Tabuchi N,Tigchelaar I,van Oeveren W

更新日期：1995-01-01 00:00:00

abstract：:Pre-eclampsia (P-EC) is a multisystem disorder exclusive to pregnancy. It complicates ~2 to 8% of all pregnancies and remains a major cause of maternal mortality. P-EC is characterized by a profound hypercoagulable state. The delicate hemostatic balance that must be maintained in the uteroplacental circulation during ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ismail SK,Higgins JR

更新日期：2011-03-01 00:00:00

abstract：:The risk for both arterial and venous thrombosis increases with age. Despite the increasing burden of strokes related to atrial fibrillation (AF) and venous thromboembolism (VTE) among older adults, the use of anticoagulant therapy is limited in this population due to the parallel increase in risk of serious hemorrhag...

journal_title：Seminars in thrombosis and hemostasis

authors： Ko D,Hylek EM

更新日期：2014-09-01 00:00:00

abstract：:The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial i...

journal_title：Seminars in thrombosis and hemostasis

authors： Niada R,Porta R,Pescador R,Mantovani M,Prino G

更新日期：1989-10-01 00:00:00

abstract：:The articular problems of patients with hemophilia begin in infancy when minor injuries result in hemarthroses. Early continuous prophylaxis (from cradle to college) is of paramount importance because the immature skeleton is very sensitive to the complications of hemophilia; severe structural deficiencies may develop...

journal_title：Seminars in thrombosis and hemostasis

authors： Rodriguez-Merchan EC,Heim M

更新日期：2005-11-01 00:00:00

abstract：:Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Peuter OR,Kok WE,Torp-Pedersen C,Büller HR,Kamphuisen PW

更新日期：2009-07-01 00:00:00

abstract：:C-type lectin-like receptor 2 (CLEC-2) has been identified on the surface of platelets as a receptor for a platelet activating snake venom, rhodocytin/aggretin. CLEC-2 belongs to a C-type lectin superfamily and binds to a sialoglycoprotein, podoplanin, in vivo. Platelets play a crucial role in hemostasis and thrombosi...

journal_title：Seminars in thrombosis and hemostasis

authors： Suzuki-Inoue K,Tsukiji N,Shirai T,Osada M,Inoue O,Ozaki Y

更新日期：2018-03-01 00:00:00

abstract：:Despite the improved therapeutic advances in the management of acute promyelocytic leukemia (APL), a significant early mortality during induction, also referred to as early death (ED), remains an obstacle for further improvement in outcome. Hemorrhagic complications are the most common cause of morbidity and mortality...

journal_title：Seminars in thrombosis and hemostasis

authors： Kwaan HC,Weiss I,Tallman MS

更新日期：2019-09-01 00:00:00

abstract：:Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clin...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Hoppensteadt D,Borris LC,Lassen MR

更新日期：1991-01-01 00:00:00

abstract：:Unfractionated heparin and LMMH were substituted with different lipophilic organic compounds. Specifically endpoint attached (LMMH-tyramine and LMMH-tyramine-FITC) and nonspecifically substituted heparins (acylated heparins, and LMMH-biotin and LMMH-cholesterol hemisuccinate) were obtained. The lipophilically substitu...

journal_title：Seminars in thrombosis and hemostasis

authors： Malsch R,Harenberg J,Guerrini M,Torri G,Casu B,Heene DL

更新日期：1994-01-01 00:00:00

abstract：UNLABELLED:We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born be...

journal_title：Seminars in thrombosis and hemostasis

authors： Batorova A,Jankovicova D,Morongova A,Bubanska E,Prigancova T,Horakova J,Machyniakova M,Cervenka J,Chandoga J,Böhmer D,Mistrik M

更新日期：2016-07-01 00:00:00

abstract：:The delicate biochemistry of coagulation and anticoagulation is greatly affected by deviations from the optimal temperature required for the interactions between various coagulation enzymes, cellular receptors, and intracellular mechanisms. Hyperthermia will lead to a prothrombotic state and, if sufficiently severe su...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2018-10-01 00:00:00

abstract：:Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

journal_title：Seminars in thrombosis and hemostasis

authors： Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

更新日期：2020-09-01 00:00:00

abstract：:Trauma remains one of the major causes of death and disability all over the world. Uncontrolled blood loss and trauma-induced coagulopathy represent preventable causes of trauma-related morbidity and mortality. Treatment may consist of allogeneic blood product transfusion at a fixed ratio or in an individualized goal-...

journal_title：Seminars in thrombosis and hemostasis

authors： Stein P,Kaserer A,Spahn GH,Spahn DR

更新日期：2017-06-01 00:00:00

abstract：:Self-control and self-management of oral anticoagulant therapy have become more and more attractive for patients undergoing long-term treatment. In our training center, we examined 50 patients who took part in a standardized training course for self-management. Patients (36 men, 14 women) were preselected according to...

journal_title：Seminars in thrombosis and hemostasis

authors： Mörsdorf S,Erdlenbruch W,Taborski U,Schenk JF,Erdlenbruch K,Novotny-Reichert G,Krischek B,Wenzel E

更新日期：1999-01-01 00:00:00

abstract：:Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

journal_title：Seminars in thrombosis and hemostasis

authors： Campbell J,Hilleman D

更新日期：2010-07-01 00:00:00

abstract：:Severe acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins...

journal_title：Seminars in thrombosis and hemostasis

authors： Onorato D,Pucci M,Carpene G,Henry BM,Sanchis-Gomar F,Lippi G

更新日期：2021-01-22 00:00:00

abstract：:Severe trauma is the leading cause of death globally. Though improved resuscitation, particularly early initiation, has reduced the 24-hour mortality rate, the overall morbidity and 30-day mortality remain high mostly due to massive hemorrhage and head injury in the early stages and sepsis and multiorgan failure later...

journal_title：Seminars in thrombosis and hemostasis

authors： Kwaan HC

更新日期：2020-03-01 00:00:00

abstract：:Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Tagliaferri A,Franchini M

更新日期：2010-02-01 00:00:00

abstract：:Anticoagulants are pivotal to achieve circulation in extracorporeal circuits. In this review we discuss several anticoagulants in clinical use or in the preclinical phase. In hemodialysis the low-molecular-weight heparins (LMWHs) appear to be as effective and safe as standard heparin (SH). The main advantages of LMWHs...

journal_title：Seminars in thrombosis and hemostasis

authors： Beijering RJ,ten Cate H,Nurmohamed MT,ten Cate JW

更新日期：1997-01-01 00:00:00

abstract：:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among m...

journal_title：Seminars in thrombosis and hemostasis

authors： Splichal JE,Stamm JA,Ornstein DL

更新日期：2003-06-01 00:00:00

abstract：:Despite long-standing knowledge about the relationship between thrombosis and atherosclerosis, the specific role of thrombin in modulating atherosclerosis and the response to vascular injury is not well understood. Thrombin receptor stimulation in vitro signals many cellular events that are associated with the respons...

journal_title：Seminars in thrombosis and hemostasis

authors： McNamara CA,Sarembock IJ,Bachhuber BG,Stouffer GA,Ragosta M,Barry W,Gimple LW,Powers ER,Owens GK

更新日期：1996-01-01 00:00:00

abstract：:While case fatality rates in ischemic stroke tend to decline, the total number of strokes is expected to increase further in the future because of more people reaching a greater age. Acute ischemic stroke, usually caused by chronic arterial hypertension, in most cases is induced either by a sudden loss of perfusion pr...

journal_title：Seminars in thrombosis and hemostasis

authors： Huber M,Heiss WD

更新日期：1996-01-01 00:00:00

abstract：:Antithrombin activity should probably be determined in persons with early onset of recurrent thrombosis, especially if a family history is present. The initial screening test should be a heparin cofactor assay optimized to reduce the contribution of heparin cofactor II. If the heparin cofactor assay is low, an antigen...

journal_title：Seminars in thrombosis and hemostasis

authors： Tollefsen DM

更新日期：1990-04-01 00:00:00

abstract：:The bidirectional interaction between coagulation and inflammation, which is relevant in various disease states that are dominated by systemic inflammatory responses, such as severe infection or chronic vascular disease, is modulated by metabolic factors. Changes in lipoprotein metabolism affect the inflammation-induc...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,Nieuwdorp M,van der Poll T,Stroes E

更新日期：2008-02-01 00:00:00

abstract：:Essential thrombocythemia (ET) is a clonal myeloproliferative disorder of unknown origin primarily involving the megakaryocyte/platelet lineage. In an attempt to evaluate the role of the receptor c-mpl and its ligand thrombopoietin (TPO) in ET, various studies have been undertaken, the results of which are discussed h...

journal_title：Seminars in thrombosis and hemostasis

authors： Griesshammer M,Bangerter M,Schrezenmeier H

更新日期：1997-01-01 00:00:00

abstract：:Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the...

journal_title：Seminars in thrombosis and hemostasis

authors： Römisch J,Bonik K,Müller HG

更新日期：1998-01-01 00:00:00

abstract：:Platelets have classically been considered crucial effector cells in hemostasis, but now are increasingly recognized as players during inflammatory responses in innate and adaptive immunity. Platelets can recognize and kill invading pathogens, and, upon stimulation, also release a wide array of mediators that modify i...

journal_title：Seminars in thrombosis and hemostasis

authors： Kim SJ,Davis RP,Jenne CN

更新日期：2018-03-01 00:00:00